Miguel Santin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6450689/publications.pdf

Version: 2024-02-01

47	2,127	394421	243625
papers	citations	19 h-index	44 g-index

50	50	50	2005
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. Lancet Infectious Diseases, The, 2022, 22, e178-e190.	9.1	51
2	Management of Drug Toxicity in Mycobacterium avium Complex Pulmonary Disease: An Expert Panel Survey. Clinical Infectious Diseases, 2021, 73, e256-e259.	5.8	16
3	Rifabutin for treating tuberculosis in solid organ transplant recipients: A retrospective observational study and literature review. Transplant Infectious Disease, 2021, 23, e13471.	1.7	4
4	Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection, 2021, 27, 288.e1-288.e4.	6.0	9
5	Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. Journal of Clinical Medicine, 2021, 10, 918.	2.4	15
6	Tuberculosis prevention in patients undergoing kidney transplantation: A nurseâ€led program for screening and treatment. Transplant Infectious Disease, 2021, 23, e13603.	1.7	3
7	Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis. Journal of Clinical Microbiology, 2021, 59, e0060321.	3.9	6
8	Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health, 2021, 9, 666187.	2.7	2
9	Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. Microbiology Spectrum, 2021, 9, e0097221.	3.0	6
10	What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?. Clinical Microbiology and Infection, 2020, 26, 1453-1455.	6.0	14
11	Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates â€“ the EUCAST broth microdilution reference method for MIC determination. Clinical Microbiology and Infection, 2020, 26, 1488-1492.	6.0	49
12	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. Frontiers in Public Health, 2020, 8, 443.	2.7	5
13	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, 905-913.	5.8	357
14	Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal, 2020, 56, 2000535.	6.7	336
15	Clinical Features Associated with Strongyloidiasis in Migrants and the Potential Impact of Immunosuppression: A Case Control Study. Pathogens, 2020, 9, 507.	2.8	8
16	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. European Respiratory Journal, 2020, 56, 2001727.	6.7	89
17	Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases, 2020, 71, e1-e36.	5.8	367
18	High Prevalence of Strongyloidiasis in Spain: A Hospital-Based Study. Pathogens, 2020, 9, 107.	2.8	7

#	Article	IF	Citations
19	Infectiousness of patients with smear-negative pulmonary tuberculosis, assessed by Real-time Polymerase Chain Reaction, Xpertâ“‡MTB/RIF. Journal of Infection, 2020, 80, 298-300.	3.3	1
20	Tumor necrosis factor antagonists for paradoxical inflammatory reactions in the central nervous system tuberculosis. Medicine (United States), 2020, 99, e22626.	1.0	14
21	Diagnosis and therapeutic approach of latent tuberculosis infection. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2018, 36, 302-311.	0.3	2
22	DiagnÃ³stico y abordaje terapÃ©utico de la infecciÃ³n tuberculosa latente. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 302-311.	0.5	14
23	Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. European Respiratory Journal, 2018, 51, 1800170.	6.7	159
24	Reply to von Reyn and Horsburgh. Clinical Infectious Diseases, 2018, 67, 1308-1309.	5.8	1
25	Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994â€“2014. Emerging Infectious Diseases, 2018, 24, 1091-1094.	4.3	28
26	Increasing isolation of rapidly growing mycobacteria in a low-incidence setting of environmental mycobacteria, 1994â€“2015. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1425-1432.	2.9	22
27	QuantiFERONÂ®-TB Gold In-Tube for contact screening in BCG-vaccinated adults: A longitudinal cohort study. PLoS ONE, 2017, 12, e0183258.	2.5	7
28	Prevention and Management of Tuberculosis in Transplant Recipients. Transplantation, 2016, 100, 1840-1852.	1.0	40
29	Executive summary of the guidelines for the use of interferon-Î³ release assays in the diagnosis of tuberculosis infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 304-308.	0.5	10
30	Sumario ejecutivo de la guÃa de prÃ¡ctica clÃnica sobre el uso de las pruebas de liberaciÃ³n de interferÃ³n-gamma para el diagnÃ³stico de infecciÃ³n tuberculosa. Archivos De Bronconeumologia, 2016, 52, 477-481.	0.8	17
31	Detection of interleukin-2 is not useful for distinguishing between latent and active tuberculosis in clinical practice: a prospective cohort study. Clinical Microbiology and Infection, 2016, 22, 1007.e1-1007.e5.	6.0	5
32	Guidelines for the use of interferon-Î³ release assays in the diagnosis of tuberculosis infection. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 303.e1-303.e13.	0.5	13
33	Linezolid for multidrug-resistant tuberculosis: How should we approach it?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 83-84.	0.5	2
34	Immunodiagnostic Testsâ€™ Predictive Values for Progression to Tuberculosis in Transplant Recipients. Transplantation Direct, 2015, 1, 1-5.	1.6	18
35	Prevention of Anti-Tumor Necrosis Factor-Associated Tuberculosis: A 10-Year Longitudinal Cohort Study. Clinical Infectious Diseases, 2015, 60, 349-356.	5.8	34
36	Interferon-Â Release Assays in Solid Organ Transplant Recipients: Everything Begins With a Single Small Step. Clinical Infectious Diseases, 2014, 58, 904-905.	5.8	1

#	Article	IF	Citations
37	T-cell-based IFN-Î³ release assays for the diagnosis of latent tuberculosis infection: have they met our expectations?. Expert Review of Molecular Diagnostics, 2013, 13, 515-517.	3.1	3
38	Interferon-Î³ release assays versus tuberculin skin test for targeting people for tuberculosis preventive treatment: An evidence-based review. Journal of Infection, 2013, 66, 381-387.	3.3	32
39	Interferon-Î³ Release Assays for the Diagnosis of Tuberculosis and Tuberculosis Infection in HIV-Infected Adults: A Systematic Review and Meta-Analysis. PLoS ONE, 2012, 7, e32482.	2.5	132
40	Detection of latent tuberculosis by the tuberculin skin test and a whole-blood interferon-Î³ release assay, and the development of active tuberculosis in HIV-seropositive persons. Diagnostic Microbiology and Infectious Disease, 2011, 69, 59-65.	1.8	27
41	Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation. Liver Transplantation, 2011, 17, 1205-1211.	2.4	44
42	Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. International Journal of Tuberculosis and Lung Disease, 2010, 14, 701-7.	1.2	21
43	Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease. European Respiratory Journal, 2009, 33, 148-152.	6.7	42
44	Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 27, 65-73.	2.9	21
45	Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against Mycobacterium kansasii. Antimicrobial Agents and Chemotherapy, 2004, 48, 4562-4565.	3.2	48
46	Mycobacterium kansasii disease among patients infected with human immunodeficiency virus type 1: improved prognosis in the era of highly active antiretroviral therapy. International Journal of Tuberculosis and Lung Disease, 2003, 7, 673-7.	1.2	14
47	Hepatic and Pulmonary Pneumocystosis During Primary Prophylaxis for Pneumocystis carinii Pneumonia with Dapsone/Pyrimethamine. Clinical Infectious Diseases, 1993, 16, 171-171.	5.8	9